http://www.fpnotebook.com/
QuetiapineAka: Seroquel
- Class
- Neuroleptic
- Dibenzothiazepine Antipsychotic
- Indications
- Schizophrenia
- Psychosis in Dementia
- Mania (not FDA approved)
- Bipolar Disorder (not FDA approved)
- Autism (not FDA approved)
- Dosing
- Adults
- Initial: 25 mg PO bid-tid
- Increase in 25-50 mg/day increments
- Target: 300-400 mg/day divided bid-tid
- Maximum dose: 750 mg/day
- Elderly
- Initial dose: 12.5 mg PO qhs
- Titrate up every few days (caution due to Sedation)
- Adverse Effects
- Sedation
- Headache
- Orthostatic Hypotension
- Cataract formation
- Monitoring
- Screen for Cataract formation every 6 months
- Pharmacokinetics
- Metabolized by Cytochrome P450 3A4
|
|---|
| Definition (NCI) | A dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | quetiapine, QUETIAPINE PREPARATION |
| Spanish | quetiapina |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | AstraZeneca Brand of Quetiapine Fumarate, Seroquel, Zeneca Brand of Quetiapine Fumarate |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree